Cardiamp cell therapy heart failure trial to be featured in two presentations at heart failure society of america annual meeting 2021

San carlos, calif., sept. 10, 2021 (globe newswire) -- biocardia®, inc.  [nasdaq: bcda], a company focused on developing cellular and cell derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces data from its cardiamp® cell therapy heart failure pivotal trial (clinicaltrials.gov identifier: nct02438306), which are being presented at the heart failure society of america annual meeting 2021 on saturday, september 11.   this year's meeting provides a hybrid format; in-person at the gaylord rockies in denver, colorado or global live on-line access.
BCDA Ratings Summary
BCDA Quant Ranking